Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy
Open Access
- 22 January 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 10, 933
Abstract
Graves' Orbitopathy (GO) is the most frequent extrathyroidal manifestation of Graves' disease (GD). Its ultimate cause remains unclear, but it is commonly considered an autoimmune disorder due to self recognition of autoantigens constitutively expressed by orbital fibroblasts (OFs), and thyroid epithelial cells. High dose intravenous glucocorticoids (ivGC) are the most commonly used treatment for moderately severe and active GO. However, based on the complex pathogenesis of GO, a number of factors may have a protective and maybe a therapeutic role. The use of other medications improving the effect of GC may increase the overall effectiveness of the therapy and reduce GC doses, thereby limiting side effects. Recently, a possible protective role of 3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors, the so-called statins, and perhaps of lowering cholesterol levels, has been proposed. Thus, statins have been reported to be associated with a reduced frequency of GO in GD patients and in recent cross-sectional and retrospective studies a significant correlation was found between the occurrence of GO and both total and LDL-cholesterol in patients with a GD of relatively recent onset, suggesting a role of cholesterol in the development of GO. Moreover, a correlation was found between the GO clinical activity score and total as well as LDL-cholesterol in untreated GO patients, depending on GO duration, indicating a role of cholesterol on GO activity. Therefore, statin treatment may be beneficial for GO. Here we review this subject, which offers new therapeutic perspectives for patients with GO.Keywords
This publication has 81 references indexed in Scilit:
- Diet Induced Mild Hypercholesterolemia in Pigs: Local and Systemic Inflammation, Effects on Vascular Injury – Rescue by High-Dose Statin TreatmentPLOS ONE, 2013
- Apoptosis, autophagy and ER stress in mevalonate cascade inhibition-induced cell death of human atrial fibroblastsCell Death & Disease, 2012
- Effects of Statin Treatment on Cardiac Function in Patients With Chronic Heart Failure: A Meta‐Analysis of Randomized Controlled TrialsClinical Cardiology, 2010
- Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trialRheumatology, 2010
- Increased immunopotency of monocyte derived dendritic cells from patients with optic neuritis is inhibited in vitro by simvastatinExperimental Neurology, 2010
- Interactions between cell death induced by statins and 7‐ketocholesterol in rabbit aorta smooth muscle cellsBritish Journal of Pharmacology, 2008
- Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple SclerosisPLOS ONE, 2008
- Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activationBlood, 2007
- Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic MechanismsNature Reviews Drug Discovery, 2005
- Statins and their potential targets in multiple sclerosis therapyExpert Opinion on Therapeutic Targets, 2003